Pharmacokinetic evaluation of a newly developed piperazine dithioctate formulation in healthy volunteers
Renhua Zheng1, Hyung Ho Song3, Young Ee Kwon3, Bo-Hyung Kim1,2
1 Department of Clinical Pharmacology and Therapeutics, 2 East-West Medical Research Institute, Kyung Hee University College of Medicine and Hospital, and 3 Korea Pharmaceutical Test & Research Institute (KPTR), Seoul, Republic of Korea
DOI 10.5414/CP202162
Abstract
Background: The formulation investigated as reference contains thioctic acid which is known to be poorly soluble in water and have some instability during storage at high temperature. To overcome these limitations, a new piperazine dithioctate (PDT) tablet formulation was developed by a domestic pharmaceutical company in Korea. Objective: The aim of this clinical study was to evaluate the pharmacokinetic characteristics of PDT in healthy volunteers. Methods: This study consisted of two clinical trials. In the part 1 study, a randomized, singledose, parallel study was performed with 24 healthy volunteers. All of the subjects were administered one of the three study formulations, Thioctacid® HR (High Release) as the reference, PDT-1 or PDT-2 (each containing thioctic acid 600 mg), respectively. To determine the harmacokinetic characteristics, blood samples were serially collected at pre-dose and at pre-defined timepoints after dosing. In the part 2 study, a randomized, single-dose, two-way crossover study was conducted with 48 subjects. All of the subjects were administered both the reference and PDT-2 formulations, with a 7-day washout period between the two medications. Blood samples were collected at the same timepoints as in the part 1 study. Tolerability was evaluated throughout the study. Results: 23 volunteers completed the part 1 study. The maximum plasma concentration (Cmax) of thioctic acid after administration of the reference tablet was 4.08 ± 2.35 μg/mL (means ± SD), and the Cmax of PDT-1 and PDT-2 was 3.53 ± 2.87 μg/mL and 4.15 ± 1.62 μg/mL, respectively. The AUClast value was 2.96 ± 1.13 μg×h/mL for the reference, 2.84 ± 1.12 μg×h/mL for PDT-1, and 3.30 ± 1.32 μg×h/mL for PDT-2. 42 volunteers completed the part 2 study. The Cmax of reference and PDT-2 was 5.59 ± 3.07 μg/mL and 5.14 ± 3.18 μg/mL, respectively. The AUClast value was 4.01 ± 1.65 μg×h/mL for the reference and 3.96 ± 1.47 μg×h/mL for PDT-2. The geometric mean ratios (PDT-2/reference) and the 90% CI for Cmax and AUClast were 0.93 (0.78 – 1.11) and 1.01 (0.94 – 1.09), respectively. Conclusion: Both studies suggested that the pharmacokinetic profile of the newly developed piperazine dithioctate formulation was comparable to the pharmacokinetic profile of the reference tablet. Both study tablets were well tolerated in all of the subjects.
Author Details
Authors
Departments
- 1 Department of Clinical Pharmacology and Therapeutics,
- 2 East-West Medical Research Institute, Kyung Hee University College of Medicine and Hospital, and
- 3 Korea Pharmaceutical Test & Research Institute (KPTR), Seoul, Republic of Korea
Address
Bo-Hyung Kim, MD, PhD
Department of Clinical Pharmacology and Therapeutics
East-West Medical Research Institute
Kyung Hee University College of Medicine and Hospital
23 Kyungheedae-ro, Dongdaemun-gu, Seoul 130-872, Korea
Email:
[email protected]
Citation
Renhua Zheng, Hyung Ho Song, Young Ee Kwon, and Bo-Hyung Kim. Pharmacokinetic evaluation of a newly developed piperazine dithioctate formulation in healthy volunteers. 2014; 52: 1083-1092. doi: 10.5414/CP202162.